...
首页> 外文期刊>Journal of Translational Medicine >Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy
【24h】

Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy

机译:癌症/睾丸抗原可作为前列腺癌根治术后生化复发的潜在预测因子

获取原文
           

摘要

Background The Cancer/Testis Antigens (CTAs) are an important group of proteins that are typically restricted to the testis in the normal adult but are aberrantly expressed in several types of cancers. As a result of their restricted expression patterns, the CTAs could serve as unique biomarkers for cancer diagnosis/prognosis. The aim of this study was to identify promising CTAs that are associated with prostate cancer (PCa) recurrence following radical prostatectomy (RP). Methods The expression of 5 CTAs was measured by quantitative multiplex real-time PCR using prostate tissue samples obtained from 72 patients with apparently clinically localized PCa with a median of two years follow-up (range, 1 to 14 years). Results The expression of CTAs namely, CEP55, NUF2, PBK and TTK were significantly higher while PAGE4 was significantly lower in patients with recurrent disease. All CTAs with the exception of TTK were significantly correlated with the prostatectomy Gleason score, but none were correlated with age, stage, or preoperative PSA levels. In univariate proportional hazards models, CEP55 (HR = 3.59, 95% CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28, 95% CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95% CI: 0.21-0.93), p = 0.031 were significantly associated with the risk of PCa recurrence. However, the results were no longer significant after adjustment for prostatectomy Gleason score. Conclusions To our knowledge, this is the first study to identify CTAs as biomarkers that can differentiate patients with recurrent and non-recurrent disease following RP and underscores its potential impact on PCa prognosis and treatment.
机译:背景技术癌症/睾丸抗原(CTAs)是一类重要的蛋白质,通常在正常成年人中仅限于睾丸,但在几种类型的癌症中异常表达。由于其受限的表达模式,CTA可以作为癌症诊断/预后的独特生物标记。这项研究的目的是确定与根治性前列腺切除术(RP)后前列腺癌(PCa)复发相关的有希望的CTA。方法采用定量实时荧光定量PCR方法,使用从72例临床上明显局限的PCa患者中获得的前列腺组织样品进行5次CTAs的表达,平均随访2年(范围为1至14年)。结果复发性疾病患者CTAs的表达明显升高,CEP55,NUF2,PBK和TTK明显升高,而PAGE4则明显降低。除TTK外,所有CTA与前列腺切除术Gleason评分均显着相关,但与年龄,分期或术前PSA水平均无相关性。在单变量比例风险模型中,CEP55(HR = 3.59,95%CI:1.50-8.60),p = 0.004; NUF 2(HR = 2.28,95%CI:1.11-4.67),p = 0.024; p = 0.024。 PAGE4(HR = 0.44,95%CI:0.21-0.93),p = 0.031与PCa复发风险显着相关。但是,调整前列腺切除术格里森评分后,结果不再显着。结论据我们所知,这是第一项将CTAs鉴定为可区分RP后复发和非复发疾病患者的生物标志物的研究,并强调了其对PCa预后和治疗的潜在影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号